Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 May;63(5):789–793. doi: 10.1038/bjc.1991.175

The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.

P E Lønning 1, S Jacobs 1, A Jones 1, B Haynes 1, T Powles 1, M Dowsett 1
PMCID: PMC1972391  PMID: 1828173

Abstract

The influence of a new aromatase inhibitor, CGS 16949A on peripheral aromatisation of androstenedione into oestrone was investigated in postmenopausal women with breast cancer. A mixture of 3H androstenedione and 14C oestrone was injected, and all urine was collected for the following 96 h. The isotope ratio was determined in the urinary oestrogen metabolites after isolation by HPLC. Eight patients were investigated before and during treatment with CGS 16949A. At a dose of 1 mg b.d. (eight patients) CGS 16949A inhibited aromatisation by a mean value of 82.4% (range 71.3 to 93.7%). When the drug dose was escalated to 2 mg b.d. (three patients) aromatisation was inhibited by a mean of 92.6% (range 90.6 to 95.8%), these results suggest that CGS 16949A at a dose of 1 mg b.d. causes submaximal aromatase inhibition in many patients, while a dose of 2 mg b.d. seems to result in greater than 90% aromatase inhibition. These data are consistent with previous observations that the higher dose is more effective in suppression of plasma oestradiol levels.

Full text

PDF
789

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bolt H. M. Metabolism of estrogens--natural and synthetic. Pharmacol Ther. 1979;4(1):155–181. doi: 10.1016/0163-7258(79)90018-4. [DOI] [PubMed] [Google Scholar]
  2. Dowsett M., Santner S. J., Santen R. J., Jeffcoate S. L., Smith I. E. Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients. Br J Cancer. 1985 Jul;52(1):31–35. doi: 10.1038/bjc.1985.144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dowsett M., Stein R. C., Mehta A., Coombes R. C. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol (Oxf) 1990 May;32(5):623–634. doi: 10.1111/j.1365-2265.1990.tb00906.x. [DOI] [PubMed] [Google Scholar]
  4. Grodin J. M., Siiteri P. K., MacDonald P. C. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab. 1973 Feb;36(2):207–214. doi: 10.1210/jcem-36-2-207. [DOI] [PubMed] [Google Scholar]
  5. Gurpide E. Metabolic influences on the action of estrogens: therapeutic implications. Pediatrics. 1978 Dec;62(6 Pt 2):1114–1120. [PubMed] [Google Scholar]
  6. Harris A. L., Dowsett M., Smith I. E., Jeffcoate S. L. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer. 1983 May;47(5):621–627. doi: 10.1038/bjc.1983.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jacobs S., Lønning P. E., Haynes B., Griggs L., Dowsett M. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzyme Inhib. 1991;4(4):315–325. doi: 10.3109/14756369109030396. [DOI] [PubMed] [Google Scholar]
  8. Lipton A., Harvey H. A., Demers L. M., Hanagan J. R., Mulagha M. T., Kochak G. M., Fitzsimmons S., Sanders S. I., Santen R. J. A phase I trial of CGS 16949A. A new aromatase inhibitor. Cancer. 1990 Mar 15;65(6):1279–1285. doi: 10.1002/1097-0142(19900315)65:6<1279::aid-cncr2820650604>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  9. Longcope C. Methods and results of aromatization studies in vivo. Cancer Res. 1982 Aug;42(8 Suppl):3307s–3311s. [PubMed] [Google Scholar]
  10. Longcope C. The metabolism of estrone sulfate in normal males. J Clin Endocrinol Metab. 1972 Jan;34(1):113–122. doi: 10.1210/jcem-34-1-113. [DOI] [PubMed] [Google Scholar]
  11. Longcope C., Williams K. I. The metabolism of estrogens in normal women after pulse injections of 3H-estradiol and 3H-estrone. J Clin Endocrinol Metab. 1974 Apr;38(4):602–607. doi: 10.1210/jcem-38-4-602. [DOI] [PubMed] [Google Scholar]
  12. Lønning P. E., Dowsett M., Jacobs S., Schem B., Hardy J., Powles T. J. Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women. J Steroid Biochem. 1989;34(1-6):551–553. doi: 10.1016/0022-4731(89)90143-x. [DOI] [PubMed] [Google Scholar]
  13. Lønning P. E., Johannessen D. C., Thorsen T. Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. Br J Cancer. 1989 Jul;60(1):107–111. doi: 10.1038/bjc.1989.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lønning P. E., Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs. 1988 Jun;35(6):685–710. doi: 10.2165/00003495-198835060-00005. [DOI] [PubMed] [Google Scholar]
  15. Lønning P. E., Kvinnsland S., Thorsen T., Ueland P. M. Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. Clin Pharmacokinet. 1987 Dec;13(6):393–406. doi: 10.2165/00003088-198713060-00004. [DOI] [PubMed] [Google Scholar]
  16. Lønning P. E., Schanche J. S., Kvinnsland S., Ueland P. M. Single-dose and steady-state pharmacokinetics of aminoglutethimide. Clin Pharmacokinet. 1985 Jul-Aug;10(4):353–364. doi: 10.2165/00003088-198510040-00005. [DOI] [PubMed] [Google Scholar]
  17. Lønning P. E., Skulstad P. Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide. J Steroid Biochem. 1989 Oct;33(4A):565–571. doi: 10.1016/0022-4731(89)90042-3. [DOI] [PubMed] [Google Scholar]
  18. Lønning P. E., Skulstad P., Sunde A., Thorsen T. Separation of urinary metabolites of radiolabelled estrogens in man by HPLC. J Steroid Biochem. 1989 Jan;32(1A):91–97. doi: 10.1016/0022-4731(89)90019-8. [DOI] [PubMed] [Google Scholar]
  19. Murray F. T., Santner S., Samojlik E., Santen R. J. Serum aminoglutethimide levels: studies of serum half-life, clearance, and patient compliance. J Clin Pharmacol. 1979 Nov-Dec;19(11-12):704–711. doi: 10.1002/j.1552-4604.1979.tb01640.x. [DOI] [PubMed] [Google Scholar]
  20. Reed M. J., Lai L. C., Owen A. M., Singh A., Coldham N. G., Purohit A., Ghilchik M. W., Shaikh N. A., James V. H. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer. Cancer Res. 1990 Jan 1;50(1):193–196. [PubMed] [Google Scholar]
  21. Ruder H. J., Loriaux L., Lipsett M. B. Estrone sulfate: production rate and metabolism in man. J Clin Invest. 1972 Apr;51(4):1020–1033. doi: 10.1172/JCI106862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Santen R. J., Santner S., Davis B., Veldhuis J., Samojlik E., Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab. 1978 Dec;47(6):1257–1265. doi: 10.1210/jcem-47-6-1257. [DOI] [PubMed] [Google Scholar]
  23. Schieweck K., Bhatnagar A. S., Matter A. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo. Cancer Res. 1988 Feb 15;48(4):834–838. [PubMed] [Google Scholar]
  24. Steele R. E., Mellor L. B., Sawyer W. K., Wasvary J. M., Browne L. J. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A. Steroids. 1987 Jul-Sep;50(1-3):147–161. doi: 10.1016/0039-128x(83)90068-5. [DOI] [PubMed] [Google Scholar]
  25. Stein R. C., Dowsett M., Davenport J., Hedley A., Ford H. T., Gazet J. C., Coombes R. C. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Cancer Res. 1990 Mar 1;50(5):1381–1384. [PubMed] [Google Scholar]
  26. Stuart-Harris R., Bradbrook I., Morrison P., Smith I. E., Rogers H. J. Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer. Br J Cancer. 1985 Apr;51(4):485–492. doi: 10.1038/bjc.1985.70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Vermeulen A., Paridaens R., Heuson J. C. Effects of aminoglutethimide on adrenal steroid secretion. Clin Endocrinol (Oxf) 1983 Dec;19(6):673–682. doi: 10.1111/j.1365-2265.1983.tb00044.x. [DOI] [PubMed] [Google Scholar]
  28. Vermeulen A. The hormonal activity of the postmenopausal ovary. J Clin Endocrinol Metab. 1976 Feb;42(2):247–253. doi: 10.1210/jcem-42-2-247. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES